News

Reverdia and Helm join forces
Enlarge image

BusinessNetherlandsFranceGermany

Reverdia and Helm join forces

18.10.2012 - Reverdia and Helm have partnered to market the bioplastics compound succinic acid on industrial scale.

Reverdia, the joint venture from Dutch DSM and French Roquette, has joined forces with Hamburg-based Helm AG for production and marketing in the highly competitive European market for bio-based succinic acid. The chemical building block for bioplastics, organic solvents and elastic fibres, is predicted to reach sales of 4-7bn annually in the mid-term.

„Reverdia’s Biosuccinium does not only offer an alternative to petrochemical succinic acid, but also for other fossil-based acids like adipic acid, so the market potential is huge”, stressed Christina Wienholz, Senior Executive Manager at Helm, who will take the part of marketing. “Our partnership with Helm will deliver expanded market development capacity for Reverdia in Europe“, said Reverdia chief Jo Kockelkoren, whose company has set up a plant-derived sugar fermentation process in yeast. His company aims at becoming the first company in the world to produce succinic acid on commercially large scale. Reverdia plans to complete a production plant with an annual capacity of 10,000 metric tons in Cassano Spinola, Italy, at the end of this year.

The move came just a week after German chemical major BASF and its Dutch partner Purac N.V. announced a joint-venture named Succinity to produce and market succinic acid. The companies want to start production after reconstruction of a 10,000 ton plant near Barcelona is finished in late 2013. US firm Myriant Inc. has also announced completion of construction of a 13,000 ton bio-succinic acid production plant in Quincy, Massachusetts, for the end of 2012. Bioamber Inc. is already marketing the bio-based compound since 2011, which is produced from E. coli in its Pomacle plant (France) that has an annual capacity of 2,000 metric tons. Succinity, however, may have a competitive edge because its process can also use glycerol, a byproduct of biodiesel production, as a feedstock.

According to the companies, biosuccinic acid could be used to produce coolants, surfactants, adhesives, corrosion inhibitors, lubricants, photo development fluids, herbicides, soldering pastes, runway deicers, polyurethanes, coating resins, phthalate-free plasticizers, polybutylene succinate (PBS) and many others.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/reverdia-and-helm-join-forces.html

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%
  • ADDEX3.30 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%

TOP

  • BIOFRONTERA2.90 EUR31.8%
  • VITA 344.32 EUR7.2%
  • BB BIOTECH157.70 EUR6.1%

FLOP

  • PAION2.24 EUR-27.7%
  • CYTOS0.16 CHF-23.8%
  • MAGFORCE5.90 EUR-16.9%

TOP

  • SANTHERA85.50 CHF2288.3%
  • CO.DON2.75 EUR183.5%
  • PAION2.24 EUR143.5%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 25.10.2014